GI
PTGX icon

GAMMA Investing’s Protagonist Therapeutics PTGX Stock Holding History

GAMMA Investing’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Buy
3,109
+208
+7% +$21.7K 0.01% 805
2026
Q1 		$306K Buy
2,901
+229
+9% +$20.3K 0.01% 834
2025
Q4 		$233K Buy
2,672
+1,024
+62% +$83.8K 0.01% 928
2025
Q3 		$109K Buy
1,648
+571
+53% +$32.5K 0.01% 1434
2025
Q2 		$59.5K Sell
1,077
-126
-10% -$6.05K ﹤0.01% 1818
2025
Q1 		$58.2K Buy
1,203
+728
+153% +$30.5K ﹤0.01% 1689
2024
Q4 		$18.3K Sell
475
-77
-14% -$3.36K ﹤0.01% 2306
2024
Q3 		$24.8K Buy
552
+487
+749% +$19.7K ﹤0.01% 1971
2024
Q2 		$2.25K Buy
65
+17
+35% +$498 ﹤0.01% 2846
2024
Q1 		$1.39K Buy
48
+23
+92% +$626 ﹤0.01% 2867
2023
Q4 		$625 Buy
+25
New +$437 ﹤0.01% 2911

Other funds holding PTGX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return
CA
Cache Advisors San Francisco, California $1.18B AUM 44.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM

GAMMA Investing's PTGX Position: Q2 2026 in Review

GAMMA Investing increased its Protagonist Therapeutics (PTGX) stake by 7.2% in Q2 2026, buying an estimated $21.7K and bringing the position to 3,109 shares worth $381K. The position accounts for 0.01% of the portfolio, ranked #805.

GAMMA Investing first reported a position in PTGX in Q4 2023 and has held it in 11 quarters since. 25 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • GAMMA Investing held 3,109 shares of Protagonist Therapeutics worth $381K as of Q2 2026.
  • GAMMA Investing bought 208 Protagonist Therapeutics shares in Q2 2026, an estimated $21.7K.
  • Protagonist Therapeutics made up 0.01% of GAMMA Investing's portfolio in Q2 2026, its #805 holding.
  • GAMMA Investing first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 25 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.